Sugi Predict

Sugi Predict / Compounds / SCHEMBL4070919

SCHEMBL4070919

SCHEMBL4070919

O=C(O)c1cc(Br)cn(-c2ccc(F)cc2)c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.57
▸ LMNA P02545 4/20 0.57
▸ ESR1 P03372 1/20 0.45
▸ ESR2 Q92731 1/20 0.45
▸ NOTUM Q6P988 1/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ MAPK1 P28482 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CNR1 P21554 1/20 0.38
▸ CNR2 P34972 1/20 0.38
▸ AXL P30530 2/20 0.38
▸ KCNH2 Q12809 1/20 0.37
▸ PTGS1 P23219 1/20 0.37
▸ PTGS2 P35354 1/20 0.37
▸ MET P08581 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29843374 0.87 MAPK1 (0.50) KDM4ELMNAESR1ESR2MEN1
SCHEMBL197601 0.86 KDM4E (0.57) KDM4ELMNAESR1ESR2NOTUM
SCHEMBL4820643 0.83 MEN1 (0.61) KDM4ELMNAMEN1KMT2AALDH1A1
SCHEMBL679241 0.82 LMNA (0.57) KDM4ELMNAESR1ESR2NOTUM
SCHEMBL21383288 0.82 MAPK1 (0.58) KDM4ELMNAESR1ESR2NOTUM
SCHEMBL30838382 0.81 MEN1 (0.47) KDM4ELMNAMEN1KMT2AALDH1A1
SCHEMBL23147088 0.79 LMNA (0.55) KDM4ELMNAESR1ESR2NOTUM
SCHEMBL21777955 0.78 LMNA (0.53) KDM4ELMNAESR1ESR2NOTUM
SCHEMBL4074927 0.78 LMNA (0.53) KDM4ELMNAESR1ESR2NOTUM
SCHEMBL21777738 0.77 LMNA (0.52) KDM4ELMNAESR1ESR2NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240293386-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR LG CHEM, LTD. (KR) 2024-09-05 — — US disclosed
US-20240174666-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2024-05-30 — — US disclosed
EP-3762392-B1 THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME WELLMARKER BIO CO LTD (KR) 2024-05-15 — — EP disclosed
US-20240150325-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS LG CHEM, LTD. (KR) 2024-05-09 — — US disclosed
EP-4332106-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR LG Chem, Ltd. (KR) 2024-03-06 — — EP disclosed
CN-117355533-A Novel compounds as protein kinase inhibitors 株式会社LG化学 2024-01-05 — — CN disclosed
EP-3843850-B1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC (US) 2023-11-15 — — EP disclosed
EP-3843850-B1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC (US) 2023-11-15 — — EP disclosed
EP-4273140-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR Lg Chem, Ltd. (KR) 2023-11-08 — — EP disclosed
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases ARRAY BIOPHARMA INC. (US) 2023-10-10 — — US disclosed
EP-1768983-A2 FUSED HETEROCYCLIC KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-04-04 — — EP disclosed
EP-1761268-A2 PYRROLOTRIAZINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-03-14 — — EP disclosed
US-7173031-B2 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-06 — — US disclosed
US-7173031-B2 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-06 — — US disclosed
US-7173031-B2 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-06 — — US disclosed
US-20060211695-A1 Fused heterocyclic kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2006-09-21 — — US disclosed
WO-2006004636-A2 FUSED HETEROCYCLIC KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-01-12 — — WO disclosed
WO-2006004833-A2 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-01-12 — — WO disclosed
US-20060004006-A1 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2006-01-05 — — US disclosed
US-20050288290-A1 Fused heterocyclic kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150325-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS MAP3K20, SBK3, MAPKAPK2 KDM4E 1700/4885LMNA 3979/4885ESR1 2232/4885
US-20050288290-A1 Fused heterocyclic kinase inhibitors MAP3K20, MAP3K19, ABL1 KDM4E 1251/4885LMNA 3824/4885ESR1 1570/4885
US-20060004006-A1 Pyrrolotriazine kinase inhibitors MAP3K5, MAP3K15, MAP4K2 KDM4E 1105/4885LMNA 4231/4885ESR1 4247/4885
US-20240174666-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES RET, MERTK, MET KDM4E 951/4885LMNA 3447/4885ESR1 602/4885
US-20060211695-A1 Fused heterocyclic kinase inhibitors MAP3K20, MAP3K19, ABL1 KDM4E 1251/4885LMNA 3824/4885ESR1 1570/4885
US-20240293386-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR MAP3K20, SBK3, MAPKAPK2 KDM4E 1510/4885LMNA 3917/4885ESR1 2343/4885
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases RET, MERTK, MET KDM4E 935/4885LMNA 3554/4885ESR1 805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.